Non-small Cell Lung Cancer
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
Your participation in this trial could last approximately 24 months, depending on your cancer type and how you and your tumor respond.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-Participants must have advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) that cannot be treated with surgery or radiation therapy
-Participants must have a RET gene fusion and sufficient tumor tissue available for confirmatory testing
-Participants must be in fair to good health and not have another serious medical condition
-Participants must not have had prior chemotherapy for metastatic lung cancer. Chemotherapy in the adjuvant/neoadjuvant setting is permitted
-Participants must not have disease that has spread to the brain and is causing symptoms
-Participants must be able to swallow capsules
Participants must be willing to use highly effective contraception during the study
Participants must not have a heart condition that puts you at risk for abnormal heart rhythms